Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Acute myelogenous leukemia-derived SMAD4 mutations target the protein to ubiquitin-proteasome degradation.
Yang L, Wang N, Tang Y, Cao X, Wan M.
Hum Mutat. 2006 Sep;27(9):897-905.
Related citations
SCF(beta-TrCP1) controls Smad4 protein stability in pancreatic cancer cells.
Wan M, Huang J, Jhala NC, Tytler EM, Yang L, Vickers SM, Tang Y, Lu C, Wang N, Cao X.
Am J Pathol. 2005 May;166(5):1379-92.
Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases.
Morén A, Imamura T, Miyazono K, Heldin CH, Moustakas A.
J Biol Chem. 2005 Jun 10;280(23):22115-23. Epub 2005 Apr 6.
Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2.
Liang M, Liang YY, Wrighton K, Ungermannova D, Wang XP, Brunicardi FC, Liu X, Feng XH, Lin X.
Mol Cell Biol. 2004 Sep;24(17):7524-37.
SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4.
Lin X, Liang M, Liang YY, Brunicardi FC, Feng XH.
J Biol Chem. 2003 Aug 15;278(33):31043-8. Epub 2003 Jun 17.
Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway.
Xu J, Attisano L.
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4820-5.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on